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Purpose: To compare adherence and persistence among patients with multiple sclerosis (MS) 
initiated on disease-modifying therapy (DMTs), including intramuscular (IM) interferon beta-1a 
(IFNβ-1a), subcutaneous (SC) IFNβ-1a, IFNβ-1b, or glatiramer acetate (GA).
Methods: MS patients initiated on IM-IFNβ-1a, SC-IFNβ-1a, IFNβ-1b, or GA between 
January 1, 2000 and January 2, 2008 were identified from a retrospective claims database study 
associated with a large US health plan. The date of DMT initiation was the index date; patients 
were observed for 6 months before and 12–36 months after the index date. Adherence to the 
index DMT was measured with a medication possession ratio (MPR), the proportion of days 
patients possessed their index DMTs; MPR $ 0.80 was considered adherent. Persistence was 
time in days from index date until the earlier of a minimum 60-day gap in DMT therapy or the 
last DMT claim during follow-up. Adherence and persistence were modeled with logistic and 
Cox proportional hazard regressions, respectively.
Results: The study population comprised 6,680 patients in the DMT cohorts: IM-IFNβ-1a 
(N = 2,305, 34.5%); IFNβ-1b (N = 894, 13.4%); GA (N = 2,270, 34.0%); and SC-IFNβ-1a 
(N = 1,211, 18.1%). The IM-IFNβ-1a cohort had significantly higher regression-adjusted 
odds of adherence relative to the other cohorts: 52.4% higher odds versus the IFNβ-1b cohort 
(OR = 0.656, CI = 0.561–0.768); 33.5% higher odds versus the GA cohort (OR = 0.749, 
CI = 0.665–0.844); and 20.6% higher odds versus the SC-IFNβ-1a cohort (OR = 0.829, 
CI = 0.719–0.957). There were no consistent differences in persistence between the cohorts.
Conclusion: IM-IFNβ-1a patients had significantly higher odds of adherence compared with 
other DMT cohorts, possibly attributable to IM-IFNβ-1a’s less frequent dosing schedule. 
The benefits of adherence may include better quality of life, lower risk of relapse, and fewer hospi-
talizations and emergency visits, making adherence a critical component of MS management.
Keywords: multiple sclerosis, immunomodulatory therapy, patient compliance
Introduction
Multiple sclerosis (MS) is an incurable, chronic inflammatory disorder of the central 
nervous system1,2 that affects approximately 2.5 million people worldwide including 
about 400,000 individuals in the United States.3 Relapsing-remitting MS (RRMS) 
is the most common form of the disease and accounts for approximately 85% of 
MS diagnoses.4 RRMS is characterized by defined and acute attacks of worsening 
neurological function (relapses) that are followed by partial or complete recovery 
(remission). While the exact pathogenesis of MS is not known, it is thought to be an 
autoimmune disorder. Females are at greater risk of developing MS than are males. Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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The risk of MS also increases with such factors as Caucasian 
race, family history of MS, and geographic origin.5 Initial 
onset of symptoms typically occurs between 20 and 40 years 
of age; diagnosis of MS after the age of 50 is rare.5
Treatment for MS focuses on disease management to 
prevent and treat relapses, manage symptoms, and slow 
disease progression. The introduction of immunomodulatory 
drugs, also referred to as disease-modifying therapy (DMT), 
in the early 1990s changed the course of patient care. Two 
interferon-β (IFNβ) products are indicated to decrease relapse 
rates and slow disability progression: subcutaneous IFNβ-1a 
(SC-IFNβ-1a, Rebif®) administered three times per week and 
intramuscular IFNβ-1a (IM-IFNβ-1a, Avonex®) administered 
once per week. Subcutaneous IFNβ-1b (Betaseron®, Extavia® 
launched in 2009), administered every other day, and glati-
ramer acetate (GA, Copaxone®) administered subcutaneously 
daily are indicated only to decrease relapse rates.6–9 Although 
other DMTs have been approved for treatment of RRMS, 
including natalizamab (Tysabri®, indicated for treatment 
after failure of first-line DMT therapy) and mitoxantrone 
(Novatrone®), interferons and GA are the predominant 
therapies prescribed upon diagnosis of MS or the decision 
to initiate treatment.
Poor adherence to medications prescribed for chronic 
conditions has been cited by the World Health Organization 
as a global problem that can lead to increased morbidity and 
mortality.10,11 Adherence is defined as the extent to which 
a patient acts in accordance with the prescribed timing, 
dosing, and frequency of medication administration.12 In MS 
research, studies have shown that patients who are adherent to 
DMTs have a lower risk of relapse than do patients who are 
non-adherent.13 Other MS studies have reported better quality 
of life for adherent patients compared with non-adherent 
patients.14,15 Adherence is measured in different ways, 
depending on the data source. In observational analyses of 
administrative claims data, adherence is measured frequently 
with a medication possession ratio (MPR) or proportion of 
days covered (PDC); these variables measure the propor-
tion of time observed during which patients possess the 
therapy of interest.12,16 MPR or PDC values range from 0.0 
to 1.0 with 1.0 indicating perfect adherence. Adherence may 
also be represented as the proportion of time during which 
patients do not have their medications (eg, cumulative gap 
ratio, continuous measure of medication gaps).16 In obser-
vational or prospective analyses of primary patient survey 
data, participants are commonly asked to recall the number 
of missed medication doses over a short period of time.14,15 
Self-reported adherence, however, may be biased toward 
overestimation of adherence due to recall bias or a desire to 
please the practitioner or investigator.17,18
Observational studies that have collected patient-
reported data have shown that patient adherence to DMTs 
is suboptimal, a consistent and compelling finding given the 
limitations with self-reported adherence. Treadaway et al14 
conducted a multicenter observational study in which MS 
patients treated with DMTs participated in an internet-based 
survey during 3 consecutive months. Patients were considered 
adherent if they did not miss any of their DMT injections in 
the 4 weeks prior to each survey. DMT adherence rates were 
61%, 63%, and 64%, respectively, during the first, second, 
and third months. Devonshire and colleagues15 assessed DMT 
adherence in a multicenter observational study of over 2,600 
patients with MS. Adherence in this study was defined as 
not missing a single dose in the 4 weeks prior to the survey 
and the authors reported an overall adherence rate of 75%.15 
A recent prospective single-center study at the University of 
Kansas Medical Center assessed adherence over an 8-week 
period in 67 patients.19 Almost 80% of patients were treated 
with GA. The study found that only 40% of patients had 
perfect adherence (missed no dose of medication) during 
the 8-week study period.19
Persistence is another measure of medication-taking 
behavior, defined as “the duration of time from initiation 
to discontinuation of therapy”.12 Persistence studies using 
administrative claims data include a pre-specified limit on the 
maximum number of days, commonly 60 or 90 days, allowed 
between refills; this limit is referred to as the “permissible gap”.12 
A patient who exceeds the permissible gap between refilling 
prescriptions is considered non-persistent.
Several studies have assessed persistence and discon-
tinuation of DMT. Tremlett and colleagues20 conducted a 
retrospective chart review of 844 MS patients who were 
prescribed interferon-beta therapy from 1995 to 2001. 
Overall, 76 of the 844 (9%) patients discontinued interferon-
beta therapy within the first 6 months. Of the 203 patients who 
were followed for at least 3 years, 61% remained on therapy 
without interruption. DMT persistence also was assessed in 
a single center, prospective study of 632 patients with MS 
who initiated therapy on interferon-beta or GA from October 
1995 through February 2004.21 The mean time of follow-up 
for the 622 patients included in the analysis was 47.1 months. 
During the entire study period, 17% of patients stopped DMT 
with almost half of those stopping during the first 2 years 
of therapy. Of the 266-patient cohort that was followed for 
at least 4 years, 212 or 80% remained on treatment with no 
interruption.21Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Limitations of the published literature on DMT adherence 
and persistence include small sample sizes,19,22 single-center 
studies,19,21 and geographically restricted populations.20,21 
Moreover, many DMT persistency studies include only inter-
feron therapy.20,22,23 Analysis with large administrative claims 
databases provides more comprehensive study populations, 
bigger study populations, and more generalizable results. 
The objective of this study was to use a large claims database 
from a national US health plan to compare adherence and 
persistence between patients initiated on interferons or GA 
and to expand findings of previous research.
Methods
study design and data source
This was a retrospective claims database study using medical 
and pharmacy data and enrollment information. The data 
included medical and pharmacy claims data and eligibility 
information from a large, national US health plan that pro-
vides fully insured coverage for professional, facility, and 
outpatient prescription pharmacy services. Medical (profes-
sional, facility) claims included International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes, ICD-9 procedure codes, Current Procedural 
Terminology, Version 4 (CPT-4) procedure codes, Health-
care Common Procedure Coding System (HCPCS) proce-
dure codes, and site of service codes. Outpatient pharmacy 
claims provided National Drug Codes (NDC) for dispensed 
medications, quantity dispensed, drug strength, and number 
of days of supply (days supply). The individuals covered 
by this health plan, 26.9 million adults during the identifi-
cation period of January 1, 2000 through January 2, 2008, 
were geographically diverse across the US, with greatest 
representation in the South and Midwest US census regions. 
All study data were accessed using techniques compliant with 
the Health Insurance Portability and Accountability Act of 
1996, and no identifiable protected health information was 
extracted during the course of the study. Because this study 
involved analysis of pre-existing, de-identified data, it was 
exempt from Institutional Review Board approval.
Patient selection
The study population was selected from commercial health 
plan members initiating DMTs. All patients had at least 
one medical claim with a primary or secondary ICD-9-CM 
diagnosis code (340) for MS and at least one medical or 
pharmacy claim for IM-IFNβ-1a, SC-IFNβ-1a, IFNβ-1b, 
or GA during the identification period of January 1, 2000 
through January 2, 2008. Patients taking IFNβ-1b marketed 
as Extavia® were not included in this analysis as the drug 
was approved in 2009, after the inclusion dates for this study. 
The date of the first observed DMT claim was defined as the 
index date and that therapy was the index DMT. Patients were 
at least 18 years old during the year of index date. Patients 
with an index DMT claim with HCPCS code J1825 (assigned 
both to IM-IFNβ-1a and SC-IFNβ-1a until 2003) and with 
no subsequent claims that would allow distinct identifica-
tion of IM-IFNβ-1a or SC-IFNβ-1a were excluded from the 
study population.
Patients were required to have continuous enrollment with 
medical and pharmacy benefits for 6 months before index 
date (baseline period) and at least 12 months follow-up, 
including the index date. The follow-up period was variable, 
up to a maximum of 36 months, in order to maximize sample 
size, and ended after the first 12 months with the earliest of: 
death, measured by patient disposition status from facility 
claims; health plan disenrollment; 3 years; or December 
31, 2008. The entire observation period was July 1, 1999 
(earliest start of baseline period) through December 31, 2008 
(latest end of follow-up period). Patients had no medical or 
pharmacy claims for any DMT during the baseline period; 
the exclusion of patients with any DMT claims during their 
baseline periods was imposed to focus on new DMT users.
Patient demographics and clinical 
characteristics
Age, gender, and geographic region of health plan enrollment 
were captured from enrollment data. Baseline clinical char-
acteristics included the Quan et al24 claims-based adaptation 
of the Charlson comorbidity index score24–26 and measures of 
MS severity. MS severity measures were binary indicators 
that identified patients with: at least one baseline MS-related 
emergency room (ER) visit; at least one baseline MS-related 
inpatient stay; and at least one baseline corticosteroid pre-
scription fill or injection (injected corticotrophin or methyl-
prednisolone, or oral dexamethasone, methylprednisolone, 
prednisolone, or prednisone).27 MS-related was defined as 
a medical claim from an ER visit or inpatient stay with a 
primary MS diagnosis.
Adherence and persistence
Adherence and persistence were measured during the 
follow-up period, including the index date. Adherence to 
index therapy was measured using MPR, calculated as: 
days supply of the index DMT divided by the days observed 
for the index DMT; days observed for the index DMT was 
number of days from the index date until the earlier of DMT Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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switch or end of follow-up period. MPR was selected as 
the adherence measure because of its focus on medication 
possession (compared with such “non-possession” measures 
as cumulative gap ratio). MPR $ 0.80 was considered 
adherent;16,28,29 MPR , 0.80 was non-adherent. Persistence 
was measured as the number of days until the earlier of the 
last DMT claim before a minimum 60-day gap in therapy 
or the last DMT claim during the follow-up period. Patients 
whose last DMT claim was 60 days or fewer before the 
end of follow-up were considered persistent throughout the 
follow-up period. The distinction between days observed for 
the index DMT and persistence was that days observed 
for the index DMT were all days that patients should have 
been on their index DMTs, including days during gaps in 
therapy, while persistence measured only the time until the 
first “permissible gap” in therapy.12,16
Analysis
Variables were analyzed descriptively. Comparisons among 
the four cohorts were performed with analysis of variance 
with Bonferonni adjustment for continuous variables and with 
chi-square statistics for categorical variables. In addition, paired 
comparisons were made between patients on IM-IFNβ-1a and 
each of the other index DMTs. A Bonferonni approximation 
was employed to adjust for the multiple paired comparisons. 
The adjusted P-value that indicated significance was 0.017 and 
was computed as (α/number of comparisons), or (0.05/3).30 
Adherence (MPR $ 0.80) was modeled with logistic 
regression. Persistence was modeled with Cox proportional 
hazard regression; the failure event was non-persistence any 
time during the follow-up period (ie, a minimum 60-day gap 
in therapy or the last observed DMT claim more than 60 days 
before the end of the follow-up period). Covariates were 
selected based on clinical importance or observed statisti-
cally significant differences in the descriptive analysis. They 
included: index DMT, age, gender, Charlson comorbidity 
index score, and indicators for baseline MS-related inpatient 
stay, baseline MS-related ER visits, and baseline corticosteroid 
utilization. Time observed for the index DMT, scaled to number 
of months (ie, days observed for the index DMT/30), was 
a covariate in the logistic regression to control for varying 
lengths of time on therapy.
Sensitivity analyses were conducted for each regression 
model. First, because SC-IFNβ-1a became available in the 
US DMT market in April 2002, separate logistic and Cox 
proportional hazard regressions were estimated for patients 
with index dates (ie, who initiated DMT therapy) after 
April 2002; these regressions captured the population for 
whom IM-IFNβ-1a, IFNβ-1b, GA, and SC-IFNβ-1a were 
available when they initiated therapy. Second, logistic regres-
sions with different adherence thresholds (MPR $ 0.70) and 
(MPR $ 0.90) were estimated for the entire study popula-
tion and for the subset of patients with index dates after 
April 2002. Third, the Cox proportional hazard regression 
was estimated using a 90-day therapy gap threshold for the 
entire study population and for the subset of patients with 
index dates after April 2002.
Results
The selection criteria yielded a study population of 6,680 
patients distributed over the four DMT cohorts: IM-IFNβ-1a 
(N = 2,305, 34.5%); IFNβ-1b (N = 894, 13.4%); GA 
(N = 2,270, 34.0%); and SC-IFNβ-1a (N = 1,211, 18.1%). 
Figure 1 depicts patient selection and attrition associated 
with each inclusion criterion.
Unadjusted analysis results
Table 1 provides the demographic and clinical characteristics 
of the DMT cohorts. There were few significant differences 
in age and gender, and significant differences in demographic 
characteristics were not clinically meaningful. The IM-IFNβ-1a 
cohort was distributed differently across Charlson comor-
bidity index score compared with the SC-IFNβ-1a cohort 
(P = 0.005). Lower proportions of the IM-IFNβ-1a cohort 
relative to the IFNβ-1b cohort had at least one MS-related 
ER visit (1.5% versus 3.5%, respectively, P , 0.001) or 
at least one MS-related inpatient stay (5.3% versus 7.6%, 
respectively, P = 0.013) during the 6-month baseline period. 
Lower proportions of the IM-IFNβ-1a cohort compared with 
the SC-IFNβ-1a cohort had at least one baseline MS-related 
inpatient stay (5.3% versus 7.8%, P = 0.003) and corticos-
teroid utilization (34.7% versus 41.9%, P , 0.001). The 
IM-IFNβ-1a cohort had a mean (standard deviation) of 743 
(322) days observed for the index therapy compared with the 
SC-IFNβ-1a cohort (692 [319] days, P , 0.001).
Unadjusted comparisons of MPR, persistence, gaps in 
therapy, and binary adherence are presented in Table 2. 
Patients in the IM-IFNβ-1a cohort had a mean MPR of 0.77 
(ie, possessed their DMTs for 77% of the days observed 
for their index therapies, on average) compared with mean 
MPR of 0.70 in the IFNβ-1b cohort (P , 0.001), 0.72 in 
the GA cohort (P , 0.001), and 0.74 in the SC-IFNβ-1a 
cohort (P = 0.010). A higher proportion of the IM-IFNβ-1a 
cohort (62.3%) was adherent at MPR $0.80 compared with 
the IFNβ-1b cohort (52.2%, P , 0.001) and the GA cohort 
(55.4%, P , 0.001). Patients treated with IM-IFNβ-1a Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Subjects with ¥1 primary or secondary multiple
sclerosis diagnosis and ¥1 disease-modifying
therapy (DMT) in identification period
1/1/2000–1/2/2008 (“original population”)  
N = 30,453 
Subjects ¥18 years old during year of index
date
N = 30,340 
(99.6% of original population) 
Subjects with index date based on 
IM-IFNβ-1a, IFNβ-1b, GA, SC-IFNβ-1a 
N = 27,920 
(91.7% of original population) 
Subjects with 6 months baseline and ¥12
months follow-up continuous enrollment  
N = 8,090  
(26.6% of original population) 
Subjects initiating therapy
(ie, no baseline DMT use)
N = 6,680, final study population 
(21.9% of original population) 
Figure 1 subject selection and attrition.
were more persistent (508 [374] days) compared with those 
treated with GA (471 [373] days, P = 0.001) and SC-IFNβ-1a 
(471 [358] days, P = 0.005).
regression results
The results of the logistic regression modeling adher-
ence at MPR $ 0.80 for the entire study population are 
shown in Table 3; in addition, the regression-adjusted 
odds ratios (ORs) for the cohort indicators are exhibited in 
Figure 2. The ORs show that the IM-IFNβ-1a cohort had 
significantly higher odds of adherence relative to the other 
cohorts: 52.4% higher odds of adherence relative to the 
IFNβ-1b cohort (OR = 0.656, CI = 0.561–0.768); 33.5% 
higher odds of adherence compared with the GA cohort 
(OR = 0.749, CI = 0.665–0.844); and 20.6% higher odds 
of adherence versus the SC-IFNβ-1a cohort (OR = 0.829, 
CI = 0.719–0.957). Males had significantly higher odds of 
adherence, as did patients with baseline corticosteroid use. 
Months observed for the index DMT was significantly and 
inversely associated with adherence, although the effect was 
small; the odds of adherence were 1% lower with each addi-
tional month patients were observed on their index DMTs.
Results from the Cox proportional hazard regression 
model of persistence estimated for the whole study popu-
lation are displayed in Table 4. There were no significant 
differences in the likelihood of failing to achieve persistence 
(ie, in having a minimum 60-day gap in therapy) between 
the IM-IFNβ-1a cohort and the IFNβ-1b or GA cohorts. 
Patients treated with SC-IFNβ-1a were 11.7% more likely 
to be non-persistent compared with the IM-IFNβ-1a cohort 
(hazard ratio = 1.117, CI = 1.013–1.233). Males were 
significantly less likely to be non-persistent and patients with 
Charlson comorbidity index scores .2 (relative to those with 
scores = 0) were significantly more likely to be non-  persistent. 
The test of proportional hazards based on   Schoenfeld 
residuals revealed that the hazard ratio associated with 
SC-IFNβ-1a was not proportional throughout the follow-up 
period (rho = -0.047, chi-square = 7.18, P = 0.007); that is, 
the hazard ratio between the IM-IFNβ-1a and SC-IFNβ-1a 
cohorts varied over the duration of the follow-up period. 
Figure 3 shows a Kaplan–Meier curve of non-persistence 
for the IM-IFNβ-1a and SC-IFNβ-1a cohorts. Consistent 
with the test of proportional hazards, Figure 3 shows that 
although the rate of non-persistence was consistently higher 
for the SC-IFNβ-1a cohort, the lines were not parallel 
throughout follow-up. Thus, the regression results indicate 
that the SC-IFNβ-1a was, on average, more likely to have 
60-day therapy gaps throughout the follow-up period.31
sensitivity analysis results
When the logistic regression to model adherence was 
estimated on the subset of patients with index dates after 
April 2002 (when all 4 DMTs were available), the ORs for 
the IFNβ-1b and GA cohorts were 0.636 (CI = 0.529–0.766) 
and 0.768 (CI = 0.670–0.880), respectively. The OR for the Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Figure 2 regression-adjusted odds ratios of adherence compared with iM-iFnβ-1a: 
all patients.
Abbreviation: iM-iFnβ-1a, intramuscular interferon beta-1a; iFnβ-1a, interferon 
beta-1b; gA, glatimer acetate; sc-iFnβ-1a, subcutaneous interferon beta-1a.
Table 3 results of logistic regression modeling adherence: all 
patients
Adherence (MPR $ 0.80)
Odds ratio 95% confidence  
interval
P-value
iFnβ-1b 0.656 (0.561–0.768) ,0.001
gA 0.749 (0.665–0.844) ,0.001
sc-iFnβ-1a 0.829 (0.719–0.957) 0.011
Age 1.011 (1.006–1.016) ,0.001
Male 1.266 (1.125–1.426) ,0.001
charlson comorbidity  
index score = 1
1.093 (0.939–1.273) 0.250
charlson comorbidity  
index score = 2
1.081 (0.888–1.316) 0.436
charlson comorbidity  
index score .2
0.790 (0.575–1.086) 0.147
Baseline Ms-related  
inpatient stay
1.061 (0.853–1.319) 0.595
Baseline Ms-related  
er visit
0.757 (0.529–1.083) 0.128
Baseline  
corticosteroid
1.138 (1.024–1.265) 0.016
Time observed  
for the index DMT  
(months)
0.990 (0.986–0.995) ,0.001
Observations 6,680
Notes:  reference  disease-modifying  therapy  =  iM-iFnβ-1a;  reference  charlson 
comorbidity index score = 0.
Abbreviations: iM-iFnβ-1a, intramuscular interferon beta-1a; iFnβ-1a, interferon 
beta-1b;  gA,  glatimer  acetate;  sc-iFnβ-1a,  subcutaneous  interferon  beta-1a; 
Ms, multiple sclerosis; er, emergency room; DMT, disease-modifying therapy.
SC-IFNβ-1a cohort was 0.877 (95% CI = 0.752–1.002) and 
not significant. The results of the primary regression, described 
above and shown in Table 3 and Figure 2, and the sensitivity 
analysis on the subset of patients with index dates after April 
2002 remained consistent when 0.70 and 0.90 adherence thresh-
olds were used as dependent variables. In the full-  population 
models, the ORs for the IFNβ-1b, GA, and SC-IFNβ-1a Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 4 results of cox proportional hazards regression modeling 
persistence: all patients
Persistence defined with 60-day gap
Hazard ratio 95% Confidence  
interval
P-value
iFnβ-1b 1.020 (0.912–1.141) 0.728
gA 1.022 (0.939–1.112) 0.612
sc-iFnβ-1a 1.117 (1.013–1.233) 0.027
Age 0.985 (0.981–0.988) ,0.001
Male 0.826 (0.759–0.899) ,0.001
charlson comorbidity  
index score = 1
1.068 (0.961–1.188) 0.221
charlson comorbidity  
index score = 2
1.119 (0.979–1.279) 0.098
charlson comorbidity  
index score . 2
1.489 (1.208–1.835) ,0.001
Baseline Ms-related  
inpatient stay
0.920 (0.791–1.071) 0.282
Baseline Ms-related  
er visit
1.149 (0.896–1.473) 0.275
Baseline  
corticosteroid
1.005 (0.934–1.082) 0.884
Observations 5,880
Notes:  reference  disease-modifying  therapy  =  iM-iFnβ-1a;  reference  charlson 
comorbidity index score = 0.
Abbreviations: iM-iFnβ-1a, intramuscular interferon beta-1a; iFnβ-1a, interferon 
beta-1b;  gA,  glatiramer  acetate;  sc-iFnβ-1a,  subcutaneous  interferon  beta-1a;   
Ms, multiple sclerosis; er, emergency room.
cohorts were below 1.0 and significant, indicating lower odds 
of adherence relative to the IM-IFNβ-1a cohort. In the models 
for the subset of the population with index dates after April 
2002, the ORs for the IFNβ-1b and GA cohorts were below 
1.0 and significant, and the OR for the SC-IFNβ-1a cohort 
was not significant (data not shown).
For patients with index dates after April 2002, the 
persistence model results showed that the hazard ratios for 
0.00
0.25
0.50
0.75
1.00
0 500 1000 100 200 300 400 600 700 800 900
Time to non-persistence (days)
IM-IFNβ-1a SC-IFNβ-1a
Figure 3 Kaplan–Meier failure curve of non-persistence.
Abbreviations: iM-iFnβ-1a, intramuscular interferon beta-1a; sc-iFnβ-1a, subcu-
taneous interferon beta-1a.
IFNβ-1b, GA, and SC-IFNβ-1a were all non-significant, at 
1.049 (CI = 0.920–1.196), 1.018 (CI = 0.924–1.121), and 
1.068 (CI = 0.962–1.187), respectively. The results shown 
in Table 4 remained consistent when the Cox proportional 
hazards regression was estimated for the entire study popu-
lation using the 90-day therapy gap threshold. When the 
persistence regression with the 90-day therapy gap definition 
was applied to the subset of patients with index dates after 
April 2002, none of the DMT cohort hazard ratios were 
significant (data not shown).
Discussion
This study analyzed patients with MS who initiated treatment 
on IM-IFNβ-1a, IFNβ-1b, GA, and SC-IFNβ-1a over an 
8-year period (1/1/2000–1/2/2008). Overall, patients treated 
with IM-IFNβ-1a had significantly higher odds of adherence 
than did patients treated with other DMTs. The results of the 
persistence analysis showed that the IM-IFNβ-1a cohort was 
more likely to be persistent (less likely to have a 60- or 90-day 
gap in therapy) than was the SC-IFNβ-1a cohort when the 
entire study population was analyzed, but not when the study 
population was limited to those who initiated treatment when 
all 4 DMTs were available; there were no significant differ-
ences in persistence between the IM-IFNβ-1a cohort and the 
GA or IFNβ-1b cohorts in any persistence regression.
The combination of adherence (measured with MPR) 
and persistence provides a more comprehensive perspec-
tive on DMT utilization than does either measure indi-
vidually. MPR shows the proportion of days that patients 
possessed their medications, but not the length of time that 
they used their medications continuously. For example, an 
MPR = 0.50 indicates that patients possessed their medi-
cations for 50% of the days they were observed: the MPR 
value = 0.50 could be achieved if patients were perfectly 
adherent for one half of their observation periods and 
perfectly non-adherent during the other half of their obser-
vation periods, or if patients had alternating 28-day periods 
with and without their medications. Persistence shows 
the duration that patients had their medications before a 
minimum gap in therapy. Persistence as typically measured,12 
however, does not account for restarting a medication after 
a gap in therapy. For instance, patients with short lengths 
of persistence could have high levels of adherence if they 
restarted their medications and used them persistently after 
their first gaps in therapy.
For our study population, regression-adjusted results 
showed that patients in the IM-IFNβ-1a cohort had signifi-
cantly higher odds of adherence than did patients on other Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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DMTs. This is important because MS is a chronic disease 
and patients need to take medication doses as required to 
achieve the optimal DMT efficacy. While we cannot observe 
patients’ actual use of their DMTs, we infer that patients 
used their DMTs at the doses prescribed because adherence 
rates were relatively high (over 70%) and the mean days on 
first-line DMTs were between 692 and 743 (Table 2); in other 
words, we assume that because patients acquired multiple 
fills of their index DMTs, they used the DMTs between fills. 
However, there were no significant (or consistently signifi-
cant) differences in persistence across cohorts, although the 
IM-IFNβ-1a cohort appeared to have a longer, unadjusted 
period of persistence. This suggests that even though patients 
in the IM-IFNβ-1a cohort had higher odds of adherence, they 
did not refill their medications continuously. This combination 
of adherence and persistence findings indicates that patients 
treated with different DMTs were equally likely to persist 
on their DMTs, but that patients in the IM-IFNβ-1a cohort 
tended to have fewer gaps in therapy, shorter gaps in therapy, 
or both over the duration of their follow-up periods.
Our findings are consistent with other studies that have 
reported higher adherence rates for patients on IM-IFNβ-1a 
compared with patients on GA, IFNB-1b, or SC-IFNβ-1a.14,15 
Devonshire reported a significantly higher adherence rate 
for patients on IM-IFNβ-1a compared with patients on 
SC-IFNβ-1a, GA, or IFNβ-1b.15 Similarly, Treadaway 
observed that patients on IM-IFNβ-1a had higher adherence 
rates than patients on SC-IFNβ-1a, GA, or IFNβ-1b.14 The 
IM-IFNβ-1a cohort in the Reynolds et al study was signifi-
cantly more adherent during the first 6 months of observation 
than were the GA, IFNβ-1B, or SC-IFNβ-1a cohorts.28 The 
IM-IFNβ-1a cohort remained significantly more adherent 
than did the GA cohort over subsequent 6-month intervals 
(7–12 months, 13–18 months), although the significance 
in differences between their IM-IFNβ-1a and IFNB-1β or 
SC-IFNβ-1a cohorts varied.28
Our findings of no significant differences in persistence 
between the IM-IFNβ-1a cohort and the other cohorts 
are largely consistent with Reynolds et al,28 who found 
no difference in regression-adjusted persistence between 
the IM-IFNβ-1a cohort and the SC-IFNβ-1a and GA 
cohorts. In contrast to our study, Reynolds observed that 
patients in the IFNβ-1b cohort were more likely than those 
in the IM-IFNβ-1a cohort to have a minimum 90-day gap 
in therapy and were less likely to be on IFNβ-1b at each 
6-month interval.
The significantly higher odds of adherence in the 
IM-IFNβ-1a cohort compared with the IFNβ-1b, 
SC-IFNβ-1a and GA cohorts could be partly attributable 
to a more convenient dosing schedule, once weekly for 
IM-IFNβ-1a compared with multiple times weekly for 
IFNβ-1b and SC-IFNβ-1a and daily for GA. In addition to 
convenience, the weekly injection schedule for IM-IFNβ-1a 
may also help allay patients’ fear of injection. More favor-
able adherence in the IM-IFNβ-1a cohort could also be a 
function of higher perceived efficacy insofar as IM-IFNβ-1a 
is indicated both to decrease the rate of relapses and to slow 
the progression of disability in RRMS. Research examining 
reasons for lack of adherence to DMT has shown that MS 
patients are more likely to be adherent when the dosing 
schedules are relatively convenient, when there are fewer 
side effects (eg, injection site reactions, flu-like symptoms, 
injection pain), and when patients perceive that their DMTs 
are beneficial.14,15,32,33 The lack of a significant difference 
in adherence between the IM-IFNβ-1a and SC-IFNβ-1a 
cohorts for subjects who initiated DMT therapy when 
SC-IFNβ-1a was available could be attributable to a “halo” 
effect with the newness of SC-IFNβ-1a; that is, MS patients 
and their providers might reasonably have been excited by 
the arrival of a new MS therapy and more likely to use it 
in an adherent manner.
Multiple studies have demonstrated the clinical, economic, 
and humanistic benefits of DMT adherence. Adherence to 
DMTs has been associated with fewer relapses,13,34 as well 
as with less health care resource use and lower costs. DMT 
adherence has also been found to be inversely related to MS-
related ER visits and hospitalizations.13,35 And, importantly, 
studies have found that MS patients who are adherent to their 
DMTs tend to report higher quality of life on such dimen-
sions as emotional health, pain, energy, and social function, 
and fewer neurological deficits.14,15
Our results indicate that patient adherence to DMTs 
could be improved. Side effects and relapses tend to be more 
prevalent early in DMT treatment and diminish over time, 
making the first year of treatment a critical time period. 
Management strategies such as dose titration, concomitant 
prophylactic therapy (eg, nonsteroidal anti-inflammatory 
drugs), use of autoinjectors, patient education on rotation 
of injection sites and safe and effective injection strate-
gies, and management of patient expectations regarding 
likely side effects could help improve tolerability early 
in the treatment regimen and in turn help improve patient 
adherence with therapy.33,36 MS patient support programs 
sponsored by DMT manufacturers (eg, Avonex® Nurse 
Services and Therapy Support program for IM-IFNβ-1a 
users,37 Shared Solutions® for GA users,38 MS LifeLines® Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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for SC-IFNβ-1a users,39 and BETAPLUS® for IFNβ-1b 
users40) and specialty care management programs provided 
by health plans35 can improve adherence to DMTs. A spe-
cialty managed care program offered in 2005 by one large 
insurer to nearly 4,000 commercial health plan enrollees 
with MS consisted of mailings of medication and disease-
specific patient education materials, assessment telephone 
calls by nurses when patients first received medication, 
periodic follow-up calls, and refill reminder calls.35 Results 
of an evaluation of this program suggested that the program 
had a positive impact on patient adherence and persistence 
as well as on hospitalization rates.35 Additionally, a series 
of articles from a summit of multidisciplinary healthcare 
providers (neurologists, nurses, nurse practitioners, and 
psychologists) in 200941–44 emphasized the importance of 
the healthcare provider–patient relationship and how nursing 
interventions, including motivational telephone counseling 
and telephone-based education and training can improve 
patient adherence by focusing on ways to combat the most 
common reasons for DMT discontinuation such as fear of 
injection, side-effects of the medication, cognitive impair-
ment, and self-efficacy.43
Limitations
Claims database studies facilitate the assessment of real-
world treatment patterns and drug-taking behavior. One 
strength of our analysis derives from a large, geographically 
diverse study population. Nevertheless, all retrospective 
database analyses are subject to certain limitations and the 
results of this study must be interpreted with appropriate 
consideration of these limitations. Pharmacy claims for 
filled prescriptions do not necessarily indicate that the 
medications were injected as prescribed. As previously 
noted, however, the high MPR suggests that patients were 
using their DMTs regularly. In addition, diagnosis codes 
on medical claims may be miscoded or “rule-out” diagno-
ses. We required both an MS diagnosis and a prescription 
for or administration of a DMT; this mitigates concerns 
regarding misclassification of MS patients in the study 
population. Claims data are constrained by coverage limi-
tations, which determine the data available and limit the 
generalizability of results to patients enrolled in similar 
managed care plans.
The most significant limitation specific to this study is 
the important unobserved and unmeasured factors that likely 
affect adherence and persistence in individuals with MS. We 
were unable to observe clinical markers or time since the 
onset or diagnosis of MS, which could provide insight into 
the progression and severity of patients’ MS. We measured 
some proxies of MS severity, such as baseline corticosteroid 
use, but we did not have access to other important clinical 
measures, such as disease severity or cognitive function. 
Moreover, we also did not have information on patients’ 
socioeconomic status, participation in therapy support 
programs, or the availability of family or friends to assist 
with medication administration. A second study limitation 
was the selection of new DMT users; patients with any 
baseline DMT use were excluded from the study popula-
tion to focus on patients who were initiating DMTs. The 
6-month baseline period was selected, in part, to maximize 
the study population size while allowing for sufficient time 
to measure covariates. It is possible that some patients in the 
study population used DMTs prior to the beginning of their 
baseline periods. We believe, however, that even in such 
cases, the patients would have been off their DMTs for long 
enough that they would be considered “naïve” DMT users, 
if not entirely new users.
Conclusion
Appropriate and persistent use of DMTs is critical for 
patients to achieve the full therapeutic value. Our study 
found that adherence rates varied among DMTs. Patients 
on IM-IFNβ-1a had significantly higher odds of adherence 
than did patients on GA, SC-IFNβ-1a, or IFNβ-1b. Patient 
benefits of adherence may include better quality of life, lower 
risk of relapse, fewer hospitalizations, and fewer ER visits. 
These benefits may also extend to the health care system as 
reduced cost due to fewer MS-related hospitalizations and 
ER visits. Additional studies are needed to better understand 
the clinical and economic implications of poor adherence 
and to develop strategies to improve patient adherence and 
persistence.
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